Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae044 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Mayu Shiomi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To determine the current retention rate of mepolizumab (MPZ) and identify factors associated with drug retention in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in the Kansai multicentre cohort (REVEAL cohort).
Methods
Sixty patients diagnosed with EGPA and treated with MPZ between December 2016 and June 2023 were enrolled. The clinical characteristics, including laboratory data, treatments administered, and disease course outcomes, were collected retrospectively. The patients were stratified into MPZ continuation (n = 53) and discontinuation (n = 7) groups, and drug retention was statistically compared using the log-rank test.
Results
The median age of patients was 54.5 years, with 55% females, and 33% antineutrophil cytoplasmic antibody-positive at disease onset. MPZ exhibited a retention rate of 78.7% after 5 years. The reasons for discontinuation included treatment of coexisting diseases, inadequate response, and remission. Patient characteristics at disease onset were comparable between the groups. Patients receiving immunosuppressants (IS) before MPZ introduction demonstrated significantly higher retention rates (P = 0.038). During the final observation, the MPZ continuation group had a lower vasculitis damage index score (P = 0.027).
Conclusions
MPZ exhibited a high 5-year retention rate, particularly in patients requiring IS. This study implies that long-term use of MPZ may mitigate irreversible organ damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan.
ORCID-Profile: Mayu Shiomi, Ryu Watanabe, Takuya Kotani, Tsuneyasu Yoshida, Keiichiro Kadoba, Ryosuke Hiwa, Motomu Hashimoto
Zitieren
APA
Shiomi, M., Watanabe, R., Matsuda, S., Kotani, T., Okazaki, A., Masuda, Y., Yoshida, T., Shoji, M., Tsuge, R., Kadoba, K., Hiwa, R., Yamamoto, W., Takeda, A., Itoh, Y., & Hashimoto, M. (2024). Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roae044
Vancouver
Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y, et al. Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study. Modern Rheumatology. 2024. doi:10.1093/mr/roae044
BibTeX
@article{Shiomi2024,
author = {Shiomi, Mayu and Watanabe, Ryu and Matsuda, Shogo and Kotani, Takuya and Okazaki, Ayana and Masuda, Yuichi and Yoshida, Tsuneyasu and Shoji, Mikihito and Tsuge, Ryosuke and Kadoba, Keiichiro and Hiwa, Ryosuke and Yamamoto, Wataru and Takeda, Akitoshi and Itoh, Yoshiaki and Hashimoto, Motomu},
title = {Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae044}
}
EUVIMED